Page 108 - Read Online

Zhang et al. Cancer Drug Resist 2024;7:34 https://dx.doi.org/10.20517/cdr.2024.59 Page 19 of 20

160. Li B, Yang L, Peng X, et al. Emerging mechanisms and applications of ferroptosis in the treatment of resistant cancers. Biomed
Pharmacother 2020;130:110710. DOI PubMed
161. Sun X, Niu X, Chen R, et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology
2016;64:488-500. DOI PubMed PMC
162. Jiang Z, Lim SO, Yan M, et al. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral
ferroptosis. J Clin Invest 2021;131:139434. DOI PubMed PMC
163. Qi R, Bai Y, Li K, et al. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer
cells by secreting exosome-derived ACSL4-targeting miRNAs. Drug Resist Updat 2023;68:100960. DOI PubMed
164. Liang J, Bi G, Huang Y, et al. MAFF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating
ferroptosis and cell cycle progression in lung adenocarcinoma. Drug Resist Updat 2024;73:101057. DOI PubMed
165. Zhang X, Xu Y, Ma L, et al. Essential roles of exosome and circRNA_101093 on ferroptosis desensitization in lung adenocarcinoma.
Cancer Commun 2022;42:287-313. DOI PubMed PMC
166. Jiang M, Jike Y, Liu K, et al. Exosome-mediated miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration,
and invasion through regulating ZEB1. Mol Cancer 2023;22:113. DOI PubMed PMC
167. Xi Y, Shen Y, Wu D, et al. CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p. Mol
Cancer 2022;21:145. DOI PubMed PMC
168. Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer
2022;21:47. DOI PubMed PMC
169. Zhang C, Xu C, Gao X, Yao Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics 2022;12:2115-32.
DOI PubMed PMC
170. Huang Y, Kou Q, Su Y, et al. Combination therapy based on dual-target biomimetic nano-delivery system for overcoming cisplatin
resistance in hepatocellular carcinoma. J Nanobiotechnology 2023;21:89. DOI PubMed PMC
171. Siemer S, Bauer TA, Scholz P, et al. Targeting cancer chemotherapy resistance by precision medicine-driven nanoparticle-formulated
cisplatin. ACS Nano 2021;15:18541-56. DOI PubMed
172. Zhang R, You X, Luo M, et al. Poly(β-cyclodextrin)/platinum prodrug supramolecular nano system for enhanced cancer therapy:
synthesis and in vivo study. Carbohydr Polym 2022;292:119695. DOI PubMed
173. Chen J, Wang X, Yuan Y, et al. Exploiting the acquired vulnerability of cisplatin-resistant tumors with a hypoxia-amplifying DNA
repair-inhibiting (HYDRI) nanomedicine. Sci Adv 2021;7:eabc5267. DOI PubMed PMC
174. Chen Y, Fang L, Zhou W, et al. Nitric oxide-releasing micelles with intelligent targeting for enhanced anti-tumor effect of cisplatin in
hypoxia. J Nanobiotechnology 2021;19:246. DOI PubMed PMC
175. Pan WL, Tan Y, Meng W, et al. Microenvironment-driven sequential ferroptosis, photodynamic therapy, and chemotherapy for
targeted breast cancer therapy by a cancer-cell-membrane-coated nanoscale metal-organic framework. Biomaterials
2022;283:121449. DOI PubMed
176. Zhang Z, Ji Y, Hu N, et al. Ferroptosis-induced anticancer effect of resveratrol with a biomimetic nano-delivery system in colorectal
cancer treatment. Asian J Pharm Sci 2022;17:751-66. DOI PubMed PMC
177. Li K, Lin C, Li M, et al. Multienzyme-like reactivity cooperatively impairs glutathione peroxidase 4 and ferroptosis suppressor
protein 1 pathways in triple-negative breast cancer for sensitized ferroptosis therapy. ACS Nano 2022;16:2381-98. DOI PubMed
178. Li K, Xu K, He Y, et al. Oxygen self-generating nanoreactor mediated ferroptosis activation and immunotherapy in triple-negative
breast cancer. ACS Nano 2023;17:4667-87. DOI PubMed
179. Chen D, Liang C, Qu X, et al. Metal-free polymer nano-photosensitizer actuates ferroptosis in starved cancer. Biomaterials
2023;292:121944. DOI PubMed
180. Liu J, Ren L, Li S, et al. The biology, function, and applications of exosomes in cancer. Acta Pharm Sin B 2021;11:2783-97. DOI
PubMed PMC
181. Wu J, Li S, Zhang P. Tumor-derived exosomes: immune properties and clinical application in lung cancer. Cancer Drug Resist
2022;5:102-13. DOI PubMed PMC
6
182. Wang Z, He J, Bach DH, et al. Induction of m A methylation in adipocyte exosomal LncRNAs mediates myeloma drug resistance. J
Exp Clin Cancer Res 2022;41:4. DOI PubMed PMC
183. Shi L, Zhu W, Huang Y, et al. Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT
pathway to promote the progression and chemoresistance of non-small cell lung cancer. Clin Transl Med 2022;12:e989. DOI
PubMed PMC
184. Pan Z, Zheng J, Zhang J, et al. A novel protein encoded by exosomal circATG4B induces oxaliplatin resistance in colorectal cancer
by promoting autophagy. Adv Sci 2022;9:e2204513. DOI PubMed PMC
185. Jing X, Xie M, Ding K, et al. Exosome-transmitted miR-769-5p confers cisplatin resistance and progression in gastric cancer by
targeting CASP9 and promoting the ubiquitination degradation of p53. Clin Transl Med 2022;12:e780. DOI PubMed PMC
186. Liu X, Guo Q, Gao G, et al. Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining
ErbB downstream signaling. J Nanobiotechnology 2023;21:45. DOI PubMed PMC
187. Deng J, Pan T, Lv C, et al. Exosomal transfer leads to chemoresistance through oxidative phosphorylation-mediated stemness
phenotype in colorectal cancer. Theranostics 2023;13:5057-74. DOI PubMed PMC
188. Zhang F, Jiang J, Qian H, Yan Y, Xu W. Exosomal circRNA: emerging insights into cancer progression and clinical application